BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17:7-19. [PMID: 20011280 DOI: 10.1055/s-2004-823066] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Zaghloul MS, Elshal M, Abdelmageed ME. Preventive empagliflozin activity on acute acetic acid-induced ulcerative colitis in rats via modulation of SIRT-1/PI3K/AKT pathway and improving colon barrier. Environ Toxicol Pharmacol 2022;:103833. [PMID: 35218923 DOI: 10.1016/j.etap.2022.103833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Javed Ansari M, Soltani A, Ramezanitaghartapeh M, Singla P, Aghaei M, Khandan Fadafan H, Ardalan Khales S, Shariati M, Shirzad-aski H, Balakheyli H, Sarim Imam S, Zafar A. Improved antibacterial activity of sulfasalazine loaded fullerene derivative: computational and experimental studies. Journal of Molecular Liquids 2022;348:118083. [DOI: 10.1016/j.molliq.2021.118083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pathan MM, Kshirsagar AD. Estimation of Mesalamine in Human Plasma Using Rapid and Sensitive LC-ESI-MS/MS Method. Pharm Chem J 2021;55:835-44. [DOI: 10.1007/s11094-021-02504-y] [Reference Citation Analysis]
4 Stewart MJ, Bessissow T, Gregor J, Hazel M, In TSH, Karra K, Dajnowiec D, Williamson M, Sattin B. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Adv Ther 2021;38:4115-29. [PMID: 34159558 DOI: 10.1007/s12325-021-01818-3] [Reference Citation Analysis]
5 Mesonero F, Juliá B, Saldaña R, Savini C, Cañas M, Cea-Calvo L, Feo-Lucas L, Fernández S, Rodríguez-Lago I; ACCU, GETECCU and GETEII. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors. Eur J Gastroenterol Hepatol 2021;33:501-7. [PMID: 32956185 DOI: 10.1097/MEG.0000000000001931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tinh NTT, Sitolo GC, Yamamoto Y, Suzuki T. Citrus limon Peel Powder Reduces Intestinal Barrier Defects and Inflammation in a Colitic Murine Experimental Model. Foods 2021;10:240. [PMID: 33503995 DOI: 10.3390/foods10020240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhang H, Zhang F, Li W. Function of intestinal barrier protected by regulating the miR-199a-3p in ulcerative colitis: Modulation of IL-23/IL-17A axis. Fundam Clin Pharmacol 2021;35:852-60. [PMID: 33475196 DOI: 10.1111/fcp.12650] [Reference Citation Analysis]
9 Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res 2021;19:419-29. [PMID: 33166442 DOI: 10.5217/ir.2020.00033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Cota D, Mishra S, Shengule S. Arjunarishta alleviates experimental colitis via suppressing proinflammatory cytokine expression, modulating gut microbiota and enhancing antioxidant effect. Mol Biol Rep 2020;47:7049-59. [PMID: 32885365 DOI: 10.1007/s11033-020-05766-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Malaekehpoor SM, Derakhshandeh K, Haddadi R, Nourian A, Ghorbani-vaghei R. A polymer coated MNP scaffold for targeted drug delivery and improvement of rheumatoid arthritis. Polym Chem 2020;11:2408-17. [DOI: 10.1039/d0py00070a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
12 Chen SQ, Song YQ, Wang C, Tao S, Yu FY, Lou HY, Hu FQ, Yuan H. Chitosan-modified lipid nanodrug delivery system for the targeted and responsive treatment of ulcerative colitis. Carbohydr Polym 2020;230:115613. [PMID: 31887935 DOI: 10.1016/j.carbpol.2019.115613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
13 Tam SYJ, Coller JK, Wignall A, Gibson RJ, Khatri A, Barbé C, Bowen JM. Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis. Ann Gastroenterol 2019;32:584-92. [PMID: 31700235 DOI: 10.20524/aog.2019.0411] [Reference Citation Analysis]
14 Actis GC, Pellicano R, Ribaldone DG. A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms. Rev Recent Clin Trials 2019;14:4-9. [PMID: 30198438 DOI: 10.2174/1574887113666180910120959] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
15 Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P, Danese S. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. Cells 2019;8:E523. [PMID: 31151306 DOI: 10.3390/cells8060523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Ehrich M, Davis J, Chauhan J, Bassaganya-Riera J. Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. Int J Toxicol 2019;38:96-109. [PMID: 30791754 DOI: 10.1177/1091581819827509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 El-Akabawy G, El-Sherif NM. Zeaxanthin exerts protective effects on acetic acid-induced colitis in rats via modulation of pro-inflammatory cytokines and oxidative stress. Biomed Pharmacother 2019;111:841-51. [PMID: 30616083 DOI: 10.1016/j.biopha.2019.01.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
18 Kanvinde S, Chhonker YS, Ahmad R, Yu F, Sleightholm R, Tang W, Jaramillo L, Chen Y, Sheinin Y, Li J, Murry DJ, Singh AB, Oupický D. Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease. Acta Biomater 2018;82:158-70. [PMID: 30342282 DOI: 10.1016/j.actbio.2018.10.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Hamanaka S, Nakagawa T, Hiwasa T, Ohta Y, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Matsumura T, Takizawa H, Kashiwado K, Kobayashi S, Matsushita K, Matsubara H, Katsuno T, Arai M, Kato N. Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis. Journal of Gastroenterology and Hepatology 2018;33:1975-83. [DOI: 10.1111/jgh.14297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Oshi MA, Naeem M, Bae J, Kim J, Lee J, Hasan N, Kim W, Im E, Jung Y, Yoo JW. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym 2018;198:434-42. [PMID: 30093020 DOI: 10.1016/j.carbpol.2018.06.107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
21 Priyam A, Shivhare K, Yadav S, Sharma AK, Kumar P. Enhanced solubility and self-assembly of amphiphilic sulfasalazine-PEG-OMe (S-PEG) conjugate into core-shell nanostructures useful for colonic drug delivery. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2018;547:157-67. [DOI: 10.1016/j.colsurfa.2018.03.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
22 Khazraei H, Bananzadeh A, Hosseini SV. Early Outcome of Patient with Ulcerative Colitis who Received High Dose of Steroid and Underwent Two Staged Total Proctocolectomy. Adv Biomed Res 2018;7:11. [PMID: 29456982 DOI: 10.4103/abr.abr_175_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Siczek K, Fichna J, Zatorski H, Karolewicz B, Klimek L, Owczarek A. Development of the rectal dosage form with silver-coated glass beads for local-action applications in lower sections of the gastrointestinal tract. Pharm Dev Technol 2018;23:295-300. [PMID: 28756715 DOI: 10.1080/10837450.2017.1359843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 Khan N, Patel D, Shah Y, Lichtenstein G, Yang Y. A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:991-7. [DOI: 10.1097/mib.0000000000001080] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
25 Kandula M, Sunil Kumar K, Palanichamy S, Rampal A. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. International Immunopharmacology 2016;40:443-51. [DOI: 10.1016/j.intimp.2016.09.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Cai M, Zeng L, Li LJ, Mo LH, Xie RD, Feng BS, Zheng PY, Liu ZG, Liu ZJ, Yang PC. Specific immunotherapy ameliorates ulcerative colitis. Allergy Asthma Clin Immunol 2016;12:37. [PMID: 27499766 DOI: 10.1186/s13223-016-0142-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
27 Bin Lan, Yang F, Lu D, Lin Z. Specific immunotherapy plus Clostridium butyricum alleviates ulcerative colitis in patients with food allergy. Sci Rep 2016;6:25587. [PMID: 27167186 DOI: 10.1038/srep25587] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
28 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
29 Prudhviraj G, Vaidya Y, Singh SK, Yadav AK, Kaur P, Gulati M, Gowthamarajan K. Effect of co-administration of probiotics with polysaccharide based colon targeted delivery systems to optimize site specific drug release. European Journal of Pharmaceutics and Biopharmaceutics 2015;97:164-72. [DOI: 10.1016/j.ejpb.2015.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
30 Sinha SR, Nguyen LP, Inayathullah M, Malkovskiy A, Habte F, Rajadas J, Habtezion A. A Thermo-Sensitive Delivery Platform for Topical Administration of Inflammatory Bowel Disease Therapies. Gastroenterology 2015;149:52-55.e2. [PMID: 25863215 DOI: 10.1053/j.gastro.2015.04.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
31 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]